Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual Meeting
The posters highlight the company's progress with Zygel, a CBD-based gel for use as a therapy for Fragile X Syndrome
Both posters will be made available on the Zynerba corporate website at http://zynerba.com/publications/
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting.
Both posters will be made available on the Zynerba corporate website.
The first poster titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]” describes responder thresholds representing individual patient-level changes that the company believes are indicative of meaningful treatment benefit for the ABC-CFXS social avoidance, irritability, and socially unresponsive/lethargic subscales. The poster was presented today (April 29).